

CORRECTION

Open Access



Correction to: Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways

Xiaolan Lian^{1,2,3†}, Yu-Min Lin^{2†}, Shingo Kozono², Megan K. Herbert², Xin Li¹, Xiaohong Yuan¹, Jiangrui Guo¹, Yafei Guo¹, Min Tang¹, Jia Lin¹, Yiping Huang¹, Bixin Wang¹, Chenxi Qiu², Cheng-Yu Tsai², Jane Xie², Ziang Jeff Gao², Yong Wu¹, Hekun Liu³, Xiao Zhen Zhou^{2,3*}, Kun Ping Lu^{2,3*} and Yuanzhong Chen^{1*}

Correction

The original article [1] contained minor typesetting errors affecting the following authors: Ziang Jeff Gao, Xiao Zhen Zhou, and Kun Ping Lu. The article has now been corrected to display the authors' names correctly.

Author details

¹Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China. ²Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. ³Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou, China.

Received: 25 June 2018 Accepted: 25 June 2018

Published online: 11 July 2018

Reference

1. Lian X, et al. Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. *J Hematol Oncol.* 2018;11:73.

* Correspondence: xzhou@bidmc.harvard.edu; klu@bidmc.harvard.edu; chenyz@mail.fjmu.edu.cn

[†]Xiaolan Lian and Yu-Min Lin contributed equally to this work.

²Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA

¹Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China

Full list of author information is available at the end of the article

